Clinical analysis of treatment on acute cerebral infarction with edaravone, batroxobin and aspirin

Objective To evaluate the efficacy and safety of the combined treatment of edaravone, batroxobin and aspirin on acute cerebral infarction. Methods The cases of acute cerebral infarction treated in our department from April, 2004 to January, 2006 were divided randomly into treatment group (n=40) and control group (n=40). The former was treated with edaravone, batroxobin and aspirin, while the latter was treated with batroxobin and aspirin. The scores of neurologic impairment were recorded before the treatment and 3, 7, 14, 28, 90 d after the treatment. The curative effects were evaluated at the 90th day. Results The treatment group had a significantly higher excellent rate and healing rate, lower side-effect rate as compared with the control group (P0.05). Conclusion The combined therapy of acute cerebral infarction with edaravone, batroxobin and aspirin is more effective and safer than that with batroxobin and aspirin only.